Complement proteins bind to nanoparticle protein corona and undergo dynamic exchange in vivo.

[1]  V. M. Holers,et al.  Modulatory Role of Surface Coating of Superparamagnetic Iron Oxide Nanoworms in Complement Opsonization and Leukocyte Uptake. , 2015, ACS nano.

[2]  Raimo Hartmann,et al.  Surface Functionalization of Nanoparticles with Polyethylene Glycol: Effects on Protein Adsorption and Cellular Uptake. , 2015, ACS nano.

[3]  Dunwei Wang,et al.  Forming buried junctions to enhance the photovoltage generated by cuprous oxide in aqueous solutions. , 2014, Angewandte Chemie.

[4]  S. Russek,et al.  High-relaxivity superparamagnetic iron oxide nanoworms with decreased immune recognition and long-circulating properties. , 2014, ACS nano.

[5]  S M Moghimi,et al.  Cancer nanomedicine and the complement system activation paradigm: anaphylaxis and tumour growth. , 2014, Journal of controlled release : official journal of the Controlled Release Society.

[6]  Warren C. W. Chan,et al.  Polyethylene glycol backfilling mitigates the negative impact of the protein corona on nanoparticle cell targeting. , 2014, Angewandte Chemie.

[7]  P. Zipfel,et al.  A Novel Antibody against Human Properdin Inhibits the Alternative Complement System and Specifically Detects Properdin from Blood Samples , 2014, PloS one.

[8]  Darren J. Martin,et al.  Cryptic epitopes of albumin determine mononuclear phagocyte system clearance of nanomaterials. , 2014, ACS nano.

[9]  Andrew Emili,et al.  Protein corona fingerprinting predicts the cellular interaction of gold and silver nanoparticles. , 2014, ACS nano.

[10]  Stefan Tenzer,et al.  Rapid formation of plasma protein corona critically affects nanoparticle pathophysiology. , 2013, Nature nanotechnology.

[11]  S. Moghimi,et al.  Complement monitoring of Pluronic 127 gel and micelles: suppression of copolymer-mediated complement activation by elevated serum levels of HDL, LDL, and apolipoproteins AI and B-100. , 2013, Journal of controlled release : official journal of the Controlled Release Society.

[12]  S. Rodríguez de Córdoba,et al.  Structural basis for the stabilization of the complement alternative pathway C3 convertase by properdin , 2013, Proceedings of the National Academy of Sciences.

[13]  Hongjie Dai,et al.  Single-walled carbon nanotube surface control of complement recognition and activation. , 2013, ACS nano.

[14]  Philip M. Kelly,et al.  Transferrin-functionalized nanoparticles lose their targeting capabilities when a biomolecule corona adsorbs on the surface. , 2013, Nature nanotechnology.

[15]  S. Rodríguez de Córdoba,et al.  Antibody directs properdin-dependent activation of the complement alternative pathway in a mouse model of abdominal aortic aneurysm , 2012, Proceedings of the National Academy of Sciences.

[16]  S M Moghimi,et al.  Factors controlling nanoparticle pharmacokinetics: an integrated analysis and perspective. , 2012, Annual review of pharmacology and toxicology.

[17]  S. Ramalingam,et al.  Bidirectional pharmacodynamic interaction between pegylated liposomal CKD-602 (S-CKD602) and monocytes in patients with refractory solid tumors , 2011, Journal of liposome research.

[18]  John D. Lambris,et al.  Protection of Nonself Surfaces from Complement Attack by Factor H-Binding Peptides: Implications for Therapeutic Medicine , 2011, The Journal of Immunology.

[19]  J. Hubbell,et al.  Engineering complement activation on polypropylene sulfide vaccine nanoparticles. , 2011, Biomaterials.

[20]  D. Simberg,et al.  Interactions of nanoparticles with plasma proteins: implication on clearance and toxicity of drug delivery systems , 2011, Expert opinion on drug delivery.

[21]  Jin Wu,et al.  Structures of C3b in Complex with Factors B and D Give Insight into Complement Convertase Formation , 2010, Science.

[22]  S Moein Moghimi,et al.  Distinct polymer architecture mediates switching of complement activation pathways at the nanosphere-serum interface: implications for stealth nanoparticle engineering. , 2010, ACS nano.

[23]  J Szebeni,et al.  Complement activation cascade triggered by PEG-PL engineered nanomedicines and carbon nanotubes: the challenges ahead. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[24]  John D Lambris,et al.  Complement: a key system for immune surveillance and homeostasis , 2010, Nature Immunology.

[25]  Thomas Vorup-Jensen,et al.  Curvature of Synthetic and Natural Surfaces Is an Important Target Feature in Classical Pathway Complement Activation , 2010, The Journal of Immunology.

[26]  H. Iwata,et al.  Complement activation by polymers carrying hydroxyl groups. , 2009, ACS applied materials & interfaces.

[27]  P. Zipfel,et al.  Complement regulators and inhibitory proteins , 2009, Nature Reviews Immunology.

[28]  Ji-Ho Park,et al.  Differential proteomics analysis of the surface heterogeneity of dextran iron oxide nanoparticles and the implications for their in vivo clearance. , 2009, Biomaterials.

[29]  Parag Aggarwal,et al.  Interaction of colloidal gold nanoparticles with human blood: effects on particle size and analysis of plasma protein binding profiles. , 2009, Nanomedicine : nanotechnology, biology, and medicine.

[30]  M. Mann,et al.  Universal sample preparation method for proteome analysis , 2009, Nature Methods.

[31]  Michael J Sailor,et al.  Systematic surface engineering of magnetic nanoworms for in vivo tumor targeting. , 2009, Small.

[32]  S. Moghimi,et al.  Poly(ethylene glycol)s generate complement activation products in human serum through increased alternative pathway turnover and a MASP-2-dependent process. , 2008, Molecular immunology.

[33]  Kenneth A. Dawson,et al.  Nanoparticle size and surface properties determine the protein corona with possible implications for biological impacts , 2008, Proceedings of the National Academy of Sciences.

[34]  S. Bhatia,et al.  Magnetic Iron Oxide Nanoworms for Tumor Targeting and Imaging , 2008, Advanced materials.

[35]  Sara Linse,et al.  Understanding the nanoparticle–protein corona using methods to quantify exchange rates and affinities of proteins for nanoparticles , 2007, Proceedings of the National Academy of Sciences.

[36]  Malcolm L. H. Green,et al.  Complement activation and protein adsorption by carbon nanotubes. , 2006, Molecular immunology.

[37]  Ajay Kumar Gupta,et al.  Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications. , 2005, Biomaterials.

[38]  Bo Nilsson,et al.  Binding of C3 fragments on top of adsorbed plasma proteins during complement activation on a model biomaterial surface. , 2005, Biomaterials.

[39]  C. Serna,et al.  Surface characterisation of dextran-coated iron oxide nanoparticles prepared by laser pyrolysis and coprecipitation , 2005 .

[40]  B. Nilsson,et al.  Material-specific thrombin generation following contact between metal surfaces and whole blood. , 2005, Biomaterials.

[41]  G. Lindahl,et al.  Human fibrinogen bound to Streptococcus pyogenes M protein inhibits complement deposition via the classical pathway , 2005, Molecular microbiology.

[42]  R. Weissleder,et al.  Method of determining nanoparticle core weight. , 2005, Analytical chemistry.

[43]  J Szebeni,et al.  Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties. , 2003, Progress in lipid research.

[44]  S. Moghimi,et al.  PEGylation of microspheres generates a heterogeneous population of particles with differential surface characteristics and biological performance , 2002, FEBS letters.

[45]  Bo Nilsson,et al.  C3 Adsorbed to a Polymer Surface Can Form an Initiating Alternative Pathway Convertase1 , 2002, The Journal of Immunology.

[46]  S M Moghimi,et al.  Long-circulating and target-specific nanoparticles: theory to practice. , 2001, Pharmacological reviews.

[47]  B. Matthews,et al.  Accurate calculation of the density of proteins. , 2000, Acta crystallographica. Section D, Biological crystallography.

[48]  K. Brunden,et al.  Inhibition of complement alternative pathway function with anti-properdin monoclonal antibodies. , 2000, Molecular immunology.

[49]  G. Borchard,et al.  The Role of Serum Complement on the Organ Distribution of Intravenously Administered Poly (methyl methacrylate) Nanoparticles: Effects of Pre-Coating with Plasma and with Serum Complement , 1996, Pharmaceutical Research.

[50]  M Gerstein,et al.  Volume changes on protein folding. , 1994, Structure.

[51]  D. Devine,et al.  Liposome-complement interactions in rat serum: implications for liposome survival studies. , 1994, Biochimica et biophysica acta.

[52]  P. Cullis,et al.  Association of blood proteins with large unilamellar liposomes in vivo. Relation to circulation lifetimes. , 1992, The Journal of biological chemistry.

[53]  M. A. Wilson,et al.  Activation and binding of opsonic fragments of C3 on encapsulated Cryptococcus neoformans by using an alternative complement pathway reconstituted from six isolated proteins , 1989, Infection and immunity.

[54]  R. Levine,et al.  Natural release of covalently bound C3b from cell surfaces and the study of this phenomenon in the fluid-phase system. , 1984, Journal of immunology.

[55]  R. Molday,et al.  Immunospecific ferromagnetic iron-dextran reagents for the labeling and magnetic separation of cells. , 1982, Journal of immunological methods.

[56]  K. Reid,et al.  The binding of complement component C3 to antibody-antigen aggregates after activation of the alternative pathway in human serum. , 1981, The Biochemical journal.

[57]  Istvan Toth,et al.  Nanoparticle-induced unfolding of fibrinogen promotes Mac-1 receptor activation and inflammation. , 2011, Nature nanotechnology.

[58]  C. Eyers.  Universal sample preparation method for proteome analysis , 2009 .

[59]  R. Müller,et al.  Influence of polysaccharide coating on the interactions of nanoparticles with biological systems. , 2006, Biomaterials.

[60]  T. Kawaguchi,et al.  Structure of dextran–magnetite complex: relation between conformation of dextran chains covering core and its molecular weight , 2000, Journal of materials science. Materials in medicine.

[61]  L. Perlemuter.  [From theory to practice]. , 1997, Soins. Psychiatrie.

[62]  C. W. Jung.  Surface properties of superparamagnetic iron oxide MR contrast agents: ferumoxides, ferumoxtran, ferumoxsil. , 1995, Magnetic resonance imaging.

[63]  D. Hochstrasser,et al.  Colloidal carriers for intravenous drug targeting: Plasma protein adsorption patterns on surface‐modified latex particles evaluated by two‐dimensional polyacrylamide gel electrophoresis , 1993, Electrophoresis.

[64]  G. Frens.  Controlled Nucleation for the Regulation of the Particle Size in Monodisperse Gold Suspensions , 1973 .

[65]  J. Millis.  Challenges ahead , 1998, Nature.